Benzothiazole derivatives as novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1

被引:58
作者
Su, XD
Vicker, N
Ganeshapillai, D
Smith, A
Purohit, A
Reed, MJ
Potter, BVL [1 ]
机构
[1] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
[2] Univ Bath, Sterix Ltd, Bath BA2 7AY, Avon, England
[3] St Marys Hosp, Imperial Coll London, Fac Med, Sterix Ltd, London W2 1NY, England
关键词
hydroxysteroid dehydrogenase; 11; beta-HSD1; inhibitors; benzothiazole; diabetes; obesity;
D O I
10.1016/j.mce.2005.10.022
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Selective inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSDl) have considerable potential as treatments for metabolic diseases, such as diabetes mellitus type 2 or obesity. Here, we report the discovery and synthesis of a series of novel benzothiazole derivatives and their inhibitory activities against 11 beta-HSDl from human hepatic microsomes measured using a radioimmunoassay (R[A) method. The benzothiazole derivatives 1 and 2 showed greater than 80% inhibition for 11 beta-HSDl at 10 mu M and exhibited IC50 values in the low micromolar range. The preliminary SAR study suggested the introduction of a chlorine substituent at the 4 position of the benzothiazole ring greatly enhanced the inhibitory activities. Docking studies with the benzothiazole derivative 1 into the crystal structure of human 11 beta-HSDl revealed how the molecule may interact with the enzyme and cofactor. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:214 / 217
页数:4
相关论文
共 11 条
[1]   Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs.: Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1 [J].
Barf, T ;
Vallgårda, J ;
Emond, R ;
Häggström, C ;
Kurz, G ;
Nygren, A ;
Larwood, V ;
Mosialou, E ;
Axelsson, K ;
Olsson, R ;
Engblom, L ;
Edling, N ;
Rönquist-Nii, Y ;
Öhman, B ;
Alberts, P ;
Abrahmsén, L .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :3813-3815
[2]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[3]  
EDWARDS CR, 1988, LANCET, V332, P986
[4]   11β-hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases [J].
Fotsch, C ;
Askew, BC ;
Chen, JJ .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (03) :289-303
[5]   Conformational flexibility in crystal structures of human 11β-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation [J].
Hosfield, DJ ;
Wu, YQ ;
Skene, RJ ;
Hilgers, M ;
Jennings, A ;
Snell, GP ;
Aertgeerts, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (06) :4639-4648
[6]   Development and validation of a genetic algorithm for flexible docking [J].
Jones, G ;
Willett, P ;
Glen, RC ;
Leach, AR ;
Taylor, R .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 267 (03) :727-748
[7]   Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2 [J].
Kotelevtsev, Y ;
Brown, RW ;
Fleming, S ;
Kenyon, C ;
Edwards, CRW ;
Seckl, JR ;
Mullins, AJ .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (05) :683-689
[8]   Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue [J].
Seckl, JR ;
Morton, NM ;
Chapman, KE ;
Walker, BR .
RECENT PROGRESS IN HORMONE RESEARCH, VOL 59, 2004, 59 :359-393
[9]   11β-hydroxysteroid dehydrogenase type 1:: A tissue-specific regulator of glucocorticoid response [J].
Tomlinson, JW ;
Walker, EA ;
Bujalska, IJ ;
Draper, N ;
Lavery, GG ;
Cooper, MS ;
Hewison, M ;
Stewart, PM .
ENDOCRINE REVIEWS, 2004, 25 (05) :831-866
[10]  
VICKER N, 2004, Patent No. 037251